Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Day One Biopharmaceuticals (DAWN) Receivables - Net (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Receivables - Net for 2 consecutive years, with $26.7 million as the latest value for Q4 2025.

  • For Q4 2025, Receivables - Net rose 92.67% year-over-year to $26.7 million; the TTM value through Dec 2025 reached $26.7 million, up 92.67%, while the annual FY2025 figure was $26.7 million, 92.67% up from the prior year.
  • Receivables - Net was $26.7 million for Q4 2025 at Day One Biopharmaceuticals, up from $16.7 million in the prior quarter.
  • The five-year high for Receivables - Net was $26.7 million in Q4 2025, with the low at $8.7 million in Q3 2024.